Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | MAPKAPK5 | Q8IW41 | 10/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 2/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674034 | 0.91 | FYN (0.50) | FYNMAPKAPK5SYKCCNE2CCNE1 | |
| SCHEMBL1674139 | 0.89 | MAPKAPK5 (0.44) | FYNMAPKAPK5SYKCCNE2CCNE1 | |
| SCHEMBL5571618 | 0.87 | MAPKAPK5 (0.48) | FYNMAPKAPK5SYKTTK | |
| SCHEMBL1674031 | 0.86 | FYN (0.39) | FYNMAPKAPK5SYKAURKAVCP | |
| SCHEMBL1674202 | 0.85 | MAPKAPK5 (0.46) | FYNMAPKAPK5SYKCCNE2CCNE1 | |
| SCHEMBL5575558 | 0.82 | MAPKAPK5 (0.49) | FYNMAPKAPK5AURKATTK | |
| SCHEMBL1674270 | 0.81 | MAPKAPK5 (0.59) | FYNMAPKAPK5SYKAURKATTK | |
| SCHEMBL3471112 | 0.75 | FYN (0.47) | FYNMAPKAPK5AURKATTK | |
| SCHEMBL1674068 | 0.74 | MAPKAPK5 (0.62) | FYNMAPKAPK5AURKA | |
| SCHEMBL1674369 | 0.72 | MAPKAPK5 (0.45) | MAPKAPK5SYKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | FYN 1514/4885MAPKAPK5 13/4885SYK 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.